EPA’s pleiotropic mechanisms of action: a narrative review

References

• Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–2223.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: a Report From the American Heart Association. Circulation. 2018;137(12):e67–e492.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13(1):26.
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213–219.
   PubMedGoogle Scholar
• Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110(17):2678–2686.
   PubMed Web of Science ®Google Scholar
• Kasai T, Miyauchi K, Yanagisawa N, et al. Mortality risk of triglyceride levels in patients with coronary artery disease. Heart. 2013;99(1):22–29.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–458.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–436.
   PubMed Web of Science ®Google Scholar
• Toth PP, Philip S, Hull M, et al. Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients. Mayo Clin Proc. 2019;94(9):1670–1680.
   PubMed Web of Science ®Google Scholar
• AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J. 2011;161(3):538–543.
   PubMed Web of Science ®Google Scholar
• The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• The FIELD Study Investigators, Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg G, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Stroes ESG. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380(1):89–90.
   PubMed Web of Science ®Google Scholar
• Jo SH, Han SH, Kim SH, et al. Cardiovascular effects of omega-3 fatty acids: hope or hype? Atherosclerosis. 2021;322:15–23.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl. 2020;22(suppl J):J32–J48.
   Web of Science ®Google Scholar
• Reinders I, Virtanen JK, Brouwer IA, et al. Association of serum n-3 polyunsaturated fatty acids with C-reactive protein in men. Eur J Clin Nutr. 2012;66(6):736–741.
   PubMed Web of Science ®Google Scholar
• Micallef MA, Munro IA, Garg ML. An inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individuals. Eur J Clin Nutr. 2009;63(9):1154–1156.
   PubMed Web of Science ®Google Scholar
• Sherratt SCR, Juliano RA, Mason RP. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochimica Et Biophysica Acta Biomembranes. 2020;1862(7):183254.
   PubMed Web of Science ®Google Scholar
• Vascepa [package insert]. Bridgewater, NJ: Amarin Pharma Inc.; 2019.
   Google Scholar
• HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events [press release] [Internet]. Toronto, Canada: HLS Therapeutics; 2019 [2020 Jan 29]. Available from: http://hlstherapeutics.investorroom.com/2019-12-31-HLS-Therapeutics-Announces-Health-Canada-Approval-for-Vascepa-R-to-Reduce-the-Risk-of-Cardiovascular-Events.
   Google Scholar
• Committee for Medicinal Products for Human Use. Summary of opinion: vazkepa [Internet]. European Medicines Agency; 2021 [2021 Mar 4]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/vazkepa.
   Google Scholar
• Vazkepa [summary of product characteristics]. Dublin, Ireland: Amarin Pharmaceuticals Ireland; 2021.
   Google Scholar
• Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–2280.
   PubMed Web of Science ®Google Scholar
• Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135–1147.
   PubMed Web of Science ®Google Scholar
• Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013;75(3):645–662.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Miller M, Steg G, et al. EPA levels and cardiovascular outcomes in the reduction of cardiovascular events with icosapent ethyl-intervention trial [oral presentation]. Chicago, IL. 2020March28–30;Annual Scientific Session of the American College of Cardiology.
   Google Scholar
• Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99–107.
   PubMed Web of Science ®Google Scholar
• Peterson BE, Bhatt DL, Steg G, et al. Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl: insights from REDUCE-IT REVAS [oral presentation]. Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions. 2020 Apr 28-May 28-May 1. Chicago, IL
   Google Scholar
• Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308–1317.
   PubMed Web of Science ®Google Scholar
• Nemiroff RL. Addressing cardiovascular risk: anti-inflammatory properties and pleiotropic effects of eicosapentaenoic acid. Contemp Ob Gyn. 2016;(suppl(3):1–8.
   Google Scholar
• Nelson JR, True WS, Le V, et al. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Postgrad Med. 2017;129(8):822–827.
   PubMed Web of Science ®Google Scholar
• Le V, Nelson JR. Eicosapentaenoic acid: pleiotrope extraordinaire? LipidSpin. 2017;15(1): 12–14. 35.
   Google Scholar
• Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357–366.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–690.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–992.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Philip S, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies Atherosclerosis. 2016;253:81–87.
   Google Scholar
• Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149.
   PubMed Web of Science ®Google Scholar
• Dunbar RL, Copland C, Jiao L, et al. Icosapent ethyl mitigates dyslipidemia by both slowing triglyceride-rich lipoprotein production and hastening LDL clearance [poster 222]. In: Annual Vascular Discovery: from Genes to Medicine Scientific Sessions. Chicago, IL; 2020May5–7.
   Google Scholar
• Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391–409.
   PubMedGoogle Scholar
• Tani S, Nagao K, Matsumoto M, et al. Highly purified eicosapentaenoic acid may increase low-density lipoprotein particle size by improving triglyceride metabolism in patients with hypertriglyceridemia. Circ J. 2013;77(9):2349–2357.
   PubMed Web of Science ®Google Scholar
• Sala-Vila A, Cofan M, Mateo-Gallego R, et al. Eicosapentaenoic acid in serum phospholipids relates to a less atherogenic lipoprotein profile in subjects with familial hypercholesterolemia. J Nutr Biochem. 2013;24(9):1604–1608.
   PubMed Web of Science ®Google Scholar
• Chinetti G, Lestavel S, Fruchart JC, et al. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res. 2003;92(2):212–217.
   PubMed Web of Science ®Google Scholar
• Reza JZ, Doosti M, Salehipour M, et al. Modulation peroxisome proliferators activated receptor alpha (PPAR alpha) and acyl coenzyme A: cholesterol acyltransferase1 (ACAT1) gene expression by fatty acids in foam cell. Lipids Health Dis. 2009;8(1):38.
   PubMed Web of Science ®Google Scholar
• Ruparelia N, Chai JT, Fisher EA, et al. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2017;14(3):133–144.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Braeckman RA, et al. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013;13(1):37–46.
   PubMed Web of Science ®Google Scholar
• Nelson JR, Raskin S. The eicosapentaenoic acid: arachidonicacid ratio and its clinical utility in cardiovascular disease. Postgrad Med. 2019;131(4):268–277.
   PubMed Web of Science ®Google Scholar
• Endo J, Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids. J Cardiol. 2016;67(1):22–27.
   PubMed Web of Science ®Google Scholar
• Gdula-Argasinska J, Czepiel J, Wozniakiewicz A, et al. n-3 Fatty acids as resolvents of inflammation in the A549 cells. Pharmacol Rep. 2015;67(3):610–615.
   PubMed Web of Science ®Google Scholar
• Arita M, Bianchini F, Aliberti J, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005;201(5):713–722.
   PubMed Web of Science ®Google Scholar
• Dona M, Fredman G, Schwab JM, et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood. 2008;112(3):848–855.
   PubMed Web of Science ®Google Scholar
• Hasturk H, Abdallah R, Kantarci A, et al. Resolvin E1 attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol. 2015;35(5):1123–1133.
   PubMed Web of Science ®Google Scholar
• Keyes KT, Ye Y, Lin Y, et al. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010;299(1):H153–164.
   PubMed Web of Science ®Google Scholar
• Salic K, Morrison MC, Verschuren L, et al. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis. 2016;250:158–165.
   PubMed Web of Science ®Google Scholar
• Ishihara T, Yoshida M, Arita M. Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. Int Immunol. 2019;31(9):559–567.
   PubMed Web of Science ®Google Scholar
• Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. 2011;111(10):5922–5943.
   PubMed Web of Science ®Google Scholar
• Zarate R, Jaber‐Vazdekis N, Tejera N, et al. Significance of long chain polyunsaturated fatty acids in human health. Clin Transl Med. 2017;6(1):25.
   PubMed Web of Science ®Google Scholar
• Lee A, Kinninger A, Jayawardena E, et al. Relationship between lipid levels and coronary atherosclerotic plaque scores by coronary computed tomography angiography (CTA) in subjects with elevated triglycerides [abstract 265]. J Clin Lipidol. 2019;13(3):e27.
   Google Scholar
• Nelson JR, Mehan MR, Alexander LE, et al. Eicosapentaenoic acid and the eicosapentaenoic acid/arachidonic acid ratio is associated with prevalent diabetes [poster]. Annual Scientific Sessions of the American Heart Association, November 11–15, 2017; Anaheim, CA.
   Google Scholar
• Sarbolouki S, Javanbakht MH, Derakhshanian H, et al. Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial. Singapore Med J. 2013;54(7):387–390.
   PubMed Web of Science ®Google Scholar
• Tishinsky JM, Ma DW, Robinson LE. Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARγ-dependent manner in human adipocytes. Obesity (Silver Spring, Md). 2011;19(2):262–268.
   PubMed Web of Science ®Google Scholar
• Lefils-Lacourtablaise J, Socorro M, Geloen A, et al. The eicosapentaenoic acid metabolite 15-deoxy-delta(12,14)-prostaglandin J3 increases adiponectin secretion by adipocytes partly via a PPARgamma-dependent mechanism. PLoS One. 2013;8(5):e63997.
   PubMed Web of Science ®Google Scholar
• Pal A, Al-Shaer AE, Guesdon W, et al. Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner. FASEB J. 2020;34(8):10640–10656.
   PubMed Web of Science ®Google Scholar
• Mullen A, Loscher CE, Roche HM. Anti-inflammatory effects of EPA and DHA are dependent upon time and dose-response elements associated with LPS stimulation in THP-1-derived macrophages. J Nutr Biochem. 2010;21(5):444–450.
   PubMed Web of Science ®Google Scholar
• Massaro M, Scoditti E, Carluccio MA, et al. Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3–5):109–115.
   PubMed Web of Science ®Google Scholar
• Allam-Ndoul B, Guenard F, Barbier O, et al. Effect of n-3 fatty acids on the expression of inflammatory genes in THP-1 macrophages. Lipids Health Dis. 2016;15(1):69.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Joshi-Barve S, Barve S, et al. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr. 2004;23(1):71–78.
   PubMed Web of Science ®Google Scholar
• Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79–82.
   PubMed Web of Science ®Google Scholar
• Takata Y, Kitami Y, Yang ZH, et al. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res. 2002;91(5):427–433.
   PubMed Web of Science ®Google Scholar
• Arita M, Ohira T, Sun YP, et al. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007;178(6):3912–3917.
   PubMed Web of Science ®Google Scholar
• Oh SF, Dona M, Fredman G, et al. Resolvin E2 formation and impact in inflammation resolution. J Immunol. 2012;188(9):4527–4534.
   PubMed Web of Science ®Google Scholar
• Isobe Y, Arita M, Matsueda S, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem. 2012;287(13):10525–10534.
   PubMed Web of Science ®Google Scholar
• Takamura M, Kurokawa K, Ootsuji H, et al. Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization. J Am Heart Assoc. 2017;6(2):2.
   Web of Science ®Google Scholar
• Chen J, Shearer GC, Chen Q, et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation. 2011;123(6):584–593.
   PubMed Web of Science ®Google Scholar
• Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101(12A):41F–50F.
   PubMed Web of Science ®Google Scholar
• Chen H, Li D, Chen J, et al. EPA and DHA attenuate ox-LDL-induced expression of adhesion molecules in human coronary artery endothelial cells via protein kinase B pathway. J Mol Cell Cardiol. 2003;35(7):769–775.
   PubMed Web of Science ®Google Scholar
• Huang CY, Sheu WH, Chiang AN. Docosahexaenoic acid and eicosapentaenoic acid suppress adhesion molecule expression in human aortic endothelial cells via differential mechanisms. Mol Nutr Food Res. 2015;59(4):751–762.
   PubMed Web of Science ®Google Scholar
• Yamada H, Yoshida M, Nakano Y, et al. In vivo and in vitro inhibition of monocyte adhesion to endothelial cells and endothelial adhesion molecules by eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2008;28(12):2173–2179.
   PubMed Web of Science ®Google Scholar
• Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27(1):229–265.
   PubMed Web of Science ®Google Scholar
• Yan Y, Jiang W, Spinetti T, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity. 2013;38(6):1154–1163.
   PubMed Web of Science ®Google Scholar
• Gonelevue S, Bandyopadhyay A, Bhagat S, et al. Sterile inflammatory role of high mobility group box 1 protein: biological functions and involvement in disease. J Vasc Res. 2018;55(4):244–254.
   PubMed Web of Science ®Google Scholar
• Sumiyoshi M, Satomi J, Kitazato KT, et al. PPARγ-dependent and -independent inhibition of the HMGB1/TLR9 pathway by eicosapentaenoic acid attenuates ischemic brain damage in ovariectomized rats. J Stroke Cerebrovasc Dis. 2015;24(6):1187–1195.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008;39(7):2052–2058.
   PubMed Web of Science ®Google Scholar
• Golzari MH, Hosseini S, Koohdani F, et al. The effect of eicosapentaenoic acid on the serum levels and enzymatic activity of paraoxonase 1 in the patients with type 2 diabetes mellitus. Acta Med Iran. 2017;55(8):486–495.
   PubMedGoogle Scholar
• Golzari MH, Javanbakht MH, Ghaedi E, et al. Effect of eicosapentaenoic acid supplementation on paraoxonase 2 gene expression in patients with type 2 diabetes mellitus: a randomized double-blind clinical trial. Clin Nutr Res. 2019;8(1):17–27.
   PubMedGoogle Scholar
• Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101(8):1581–1590.
   PubMed Web of Science ®Google Scholar
• Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol. 2003;23(3):461–467.
   PubMed Web of Science ®Google Scholar
• Rozenberg O, Shih DM, Paraoxonase AM. 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis. 2005;181(1):9–18.
   PubMed Web of Science ®Google Scholar
• Mason RP, Sherratt SCR, Jacob RF. Eicosapentaenoic acid inhibits oxidation of apoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J Cardiovasc Pharmacol. 2016;68(1):33–40.
   PubMed Web of Science ®Google Scholar
• Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335–338.
   PubMed Web of Science ®Google Scholar
• Dyerberg J, Bang HO, Stoffersen E, et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978;2(8081):117–119.
   PubMed Web of Science ®Google Scholar
• Fredman G, Van Dyke TE, Serhan CN. Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol. 2010;30(10):2005–2013.
   PubMed Web of Science ®Google Scholar
• Gong Y, Lin M, Piao L, et al. Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling. Br J Pharmacol. 2015;172(23):5647–5660.
   PubMed Web of Science ®Google Scholar
• Mason RP. New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep. 2019;21(1):2.
   PubMed Web of Science ®Google Scholar
• Williams JA, Batten SE, Harris M, et al. Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains. Biophys J. 2012;103(2):228–237.
   PubMed Web of Science ®Google Scholar
• Leng X, Kinnun JJ, Cavazos AT, et al. All n-3 PUFA are not the same: MD simulations reveal differences in membrane organization for EPA, DHA and DPA. Biochimica Et Biophysica Acta Biomembranes. 2018;1860(5):1125–1134.
   PubMed Web of Science ®Google Scholar
• Mason RP, Jacob RF. Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim Biophys Acta. 2015;1848(2):502–509.
   PubMed Web of Science ®Google Scholar
• Mason RP, Jacob RF. Membrane microdomains and vascular biology: emerging role in atherogenesis. Circulation. 2003;107(17):2270–2273.
   PubMed Web of Science ®Google Scholar
• Mason RP, Jacob RF, Shrivastava S, et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858(12):3131–3140.
   PubMed Web of Science ®Google Scholar
• Moreno C, De La Cruz A, Oliveras A, et al. Marine n-3 PUFAs modulate IKs gating, channel expression, and location in membrane microdomains. Cardiovasc Res. 2015;105(2):223–232.
   PubMed Web of Science ®Google Scholar
• Li GR, Sun HY, Zhang XH, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+current in human atrial myocytes. Cardiovasc Res. 2009;81(2):286–293.
   PubMed Web of Science ®Google Scholar
• Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci U S A. 1992;89(5):1760–1764.
   PubMed Web of Science ®Google Scholar
• Kromhout D, Geleijnse JM, De GJ, et al. n-3 Fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care. 2011;34(12):2515–2520.
   PubMed Web of Science ®Google Scholar
• Chen WT, Chen SY, Wu DW, et al. Effect of icosapent ethyl on susceptibility to ventricular arrhythmias in postinfarcted rat hearts: role of GPR120-mediated connexin43 phosphorylation. J Cell Mol Med. 2020;24(16):9267–9279.
   PubMed Web of Science ®Google Scholar
• Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J. 2012;59(4):297–304.
   PubMed Web of Science ®Google Scholar
• Toyama K, Nishioka T, Isshiki A, et al. Eicosapentaenoic acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014;28(1):53–59.
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Shimabukuro M, Higa N, et al. Eicosapentaenoic acid supplementation changes fatty acid composition and corrects endothelial dysfunction in hyperlipidemic patients. Cardiol Res Pract. 2012;2012:754181.
   PubMedGoogle Scholar
• Takaki A, Umemoto S, Ono K, et al. Add-on therapy of EPA reduces oxidative stress and inhibits the progression of aortic stiffness in patients with coronary artery disease and statin therapy: a randomized controlled study. J Atheroscler Thromb. 2011;18(10):857–866.
   PubMed Web of Science ®Google Scholar
• O’Connell TD, Mason RP, Budoff MJ, et al. Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. Eur Heart J Suppl. 2020;22(suppl J):J3–J20.
   PubMed Web of Science ®Google Scholar
• Mason RP, Dawoud H, Jacob RF, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018;103:1231–1237.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Kampoli AM, Tentolouris C, et al. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10(1):4–18.
   PubMed Web of Science ®Google Scholar
• Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res. 2007;48(8):1673–1680.
   PubMed Web of Science ®Google Scholar
• Demer LL, Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol. 2014;34(4):715–723.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Miura D, Saito Y, et al. Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice. PLoS One. 2017;12(8):e0181009.
   PubMed Web of Science ®Google Scholar
• Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687–698.
   PubMed Web of Science ®Google Scholar
• MacRitchie N, Resolvin MP. E1 for reducing vascular calcification. Cardiovasc Res. 2019;115(10):1457–1459.
   PubMed Web of Science ®Google Scholar
• Devaraj S, Chien A, Rao B, et al. Modulation of endothelial progenitor cell number and function with n-3 polyunsaturated fatty acids. Atherosclerosis. 2013;228(1):94–97.
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999–1007.
   PubMed Web of Science ®Google Scholar
• Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593–600.
   PubMed Web of Science ®Google Scholar
• Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler Thromb Vasc Biol. 2006;26(2):257–266.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Ishida T, Nagao M, et al. Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis. 2014;237(2):577–583.
   PubMed Web of Science ®Google Scholar
• Tithof PK, Elgayyar M, Schuller HM, et al. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, a nicotine derivative, induces apoptosis of endothelial cells. Am J Physiol Heart Circ Physiol. 2001;281(5):H1946–H1954.
   PubMed Web of Science ®Google Scholar
• Nelson JR, Wani O, May HT, et al. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1–9.
   PubMed Web of Science ®Google Scholar
• Nishio R, Shinke T, Otake H, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234(1):114–119.
   PubMed Web of Science ®Google Scholar
• Sakakura K, Nakano M, Otsuka F, et al. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ. 2013;22(6):399–411.
   PubMed Web of Science ®Google Scholar
• Uehara H, Miyagi N, Shimajiri M, et al. The additional effect of eicosapentanoic acid on coronary plaque stability in stable angina patients with statin use by optical coherence tomography analysis [abstract P5495]. Eur Heart J. 2013;34(suppl 1):1011.
   Google Scholar
• Nagahara Y, Motoyama S, Sarai M, et al. Eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio as an associated factor of high risk plaque on coronary computed tomography in patients without coronary artery disease. Atherosclerosis. 2016;250:30–37.
   PubMed Web of Science ®Google Scholar
• Nakajima K, Yamashita T, Kita T, et al. Orally administered eicosapentaenoic acid induces rapid regression of atherosclerosis via modulating the phenotype of dendritic cells in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31(9):1963–1972.
   PubMed Web of Science ®Google Scholar
• Fujiyoshi K, Minami Y, Ishida K, et al. Incidence, factors, and clinical significance of cholesterol crystals in coronary plaque: an optical coherence tomography study. Atherosclerosis. 2019;283:79–84.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Irino Y, Shinohara M, et al. Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties. Circ J. 2018;82(2):596–601.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70(6):537–544.
   PubMed Web of Science ®Google Scholar
• Konishi T, Sunaga D, Funayama N, et al. Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging. Clin Cardiol. 2019;42(6):618–628.
   PubMed Web of Science ®Google Scholar
• Niki T, Wakatsuki T, Yamaguchi K, et al. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. Circ J. 2016;80(2):450–460.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925–3932.
   PubMed Web of Science ®Google Scholar
• Lakshmanan S, Shekar C, Kinninger A, et al. Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. Cardiovasc Res. 2020;116(3):479–482.
   PubMed Web of Science ®Google Scholar
• Alfaddagh A, Elajami TK, Ashfaque H, et al. Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. J Am Heart Assoc. 2017;6(12):12.
   Web of Science ®Google Scholar
• Gower RM, Wu H, Foster GA, et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol. 2011;31(1):160–166.
   PubMed Web of Science ®Google Scholar
• Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000;192(8):1197–1204.
   PubMed Web of Science ®Google Scholar
• Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells. Arterioscler Thromb Vasc Biol. 2015;35(2):280–287.
   PubMed Web of Science ®Google Scholar
• Onodera T, Fukuhara A, Shin J, et al. Eicosapentaenoic acid and 5-HEPE enhance macrophage-mediated Treg induction in mice. Sci Rep. 2017;7(1):4560.
   PubMed Web of Science ®Google Scholar
• Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6(2):131–138.
   PubMedGoogle Scholar
• Kim TH, Kim GD, Jin YH, et al. Omega-3 fatty acid-derived mediator, Resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int Immunopharmacol. 2012;14(4):384–391.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233–240.
   PubMed Web of Science ®Google Scholar
• Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–2587.
   PubMed Web of Science ®Google Scholar
• Haworth O, Cernadas M, Yang R, et al. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol. 2008;9(8):873–879.
   PubMed Web of Science ®Google Scholar
• Le PNT, Desbois AP. Antibacterial effect of eicosapentaenoic acid against bacillus cereus and staphylococcus aureus: killing kinetics, selection for resistance, and potential cellular target. Mar Drugs. 2017;15(11):334.
   PubMed Web of Science ®Google Scholar
• Shin SY, Bajpai VK, Kim HR, et al. Antibacterial activity of bioconverted eicosapentaenoic (EPA) and docosahexaenoic acid (DHA) against foodborne pathogenic bacteria. Int J Food Microbiol. 2007;113(2):233–236.
   PubMed Web of Science ®Google Scholar
• Cheng CL, Huang SJ, Wu CL, et al. Transgenic expression of omega-3 PUFA synthesis genes improves zebrafish survival during Vibrio vulnificus infection. J Biomed Sci. 2015;22(1):103.
   PubMed Web of Science ®Google Scholar
• Desbois AP, Lawlor KC. Antibacterial activity of long-chain polyunsaturated fatty acids against Propionibacterium acnes and Staphylococcus aureus. Mar Drugs. 2013;11(11):4544–4557.
   PubMed Web of Science ®Google Scholar
• D’Elia RV, Harrison K, Oyston PC, et al. Targeting the. “cytokine storm” for therapeutic benefit. Clin Vaccine Immunol. 2013;20(3):319–327.
   PubMedGoogle Scholar
• Mo Z, Tang C, Li H, et al. Eicosapentaenoic acid prevents inflammation induced by acute cerebral infarction through inhibition of NLRP3 inflammasome activation. Life Sci. 2020;242:117133.
   PubMed Web of Science ®Google Scholar
• Goc A, Niedzwiecki A, Polyunsaturated RM. ω-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry. Sci Rep. 2021;11(1):5207.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Malik UI, Thomas RC, et al. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021;235:54–64.
   PubMed Web of Science ®Google Scholar
• Asher A, Tintle NL, Myers M, et al. Blood omega-3 fatty acids and death from COVID-19: a pilot study. Prostaglandins Leukot Essent Fatty Acids. 2021;166:102250.
   PubMed Web of Science ®Google Scholar
• Kosmopoulos A, Verma S, Meglis G, et al. VASCEPA COVID-19 CardioLink-9: first human trial of a loading dose of icosapent ethyl in patients with COVID-19 [presentation]. Annual Scientific Sessions of the National Lipid Association, December 10–12, 2020 ( virtual).
   Google Scholar
• Suh W, Urits I, Viswanath O, et al. Three cases of COVID-19 pneumonia that responded to icosapent ethyl supportive treatment. Am J Case Reps. 2020;21:e928422.
   Google Scholar
• Pal A, Gowdy KM, Oestreich KJ, et al. Obesity-driven deficiencies of specialized pro-resolving mediators may drive adverse outcomes during SARS-CoV-2 infection. Front Immunol. 2020;11:1997.
   PubMed Web of Science ®Google Scholar
• Simopoulos AP, Serhan CN, Bazinet RP. The need for precision nutrition, genetic variation and resolution in Covid-19 patients. Mol Aspects Med. 2021;77:100943.
   PubMed Web of Science ®Google Scholar